Stock Price Quote

CIPLA LTD.

NSE : CIPLABSE : 500087ISIN CODE : INE059A01026Industry : Pharmaceuticals & DrugsHouse : Cipla
BSE1405.406.6 (+0.47 %)
PREV CLOSE ( ) 1398.80
OPEN PRICE ( ) 1409.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 37145
TODAY'S LOW / HIGH ( )1384.40 1410.25
52 WK LOW / HIGH ( )896.1 1519
NSE1406.208 (+0.57 %)
PREV CLOSE( ) 1398.20
OPEN PRICE ( ) 1407.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1406.20 (3201)
VOLUME 2027213
TODAY'S LOW / HIGH( ) 1384.10 1410.45
52 WK LOW / HIGH ( )896.3 1519
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 17-08 1935
Management Info
Y K Hamied - Chairman Umang Vohra - Managing Director
Registered Office

Address Cipla House, Peninsula Business Park,Ganpatrao Kadam Marg,Lower Parel,
Mumbai,
Maharashtra-400013

Phone 022-24826000

Email contactus@cipla.com

Website www.cipla.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Luxembourg, MCX

NEWS

18Apr Announcement under Regulation 30 (LOD
In compliance with the provisions of Regulation 30 (Listing Obligations..
16Apr Cipla, Deep Industries and Bharti Airt
Cipla Health (CHL), the wholly owned subsidiary and consumer healthcare..
16Apr Cipla's arm signs agreement for acquis
Cipla Health (CHL), the wholly owned subsidiary and consumer healthcare..
16Apr Cipla informs about allotment of equit
In compliance with the provisions of Regulation 30 of SEBI (Listing Obli..
08Apr USFDA Inspection At Company'S Manufac
USFDA inspection at Company''s manufacturing facility in Patalganga, Mah..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit11141.425134.7
Gross Profit 13807.6 34405.4
Operating Profit 15248.442493.7
Net Sales 43813.3157906

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Dr. Reddy's Lab (BSE)
peergroup  6217.15 (4.47%)
M.Cap ( in Cr)103713.42
Abbott India (BSE)
peergroup  25725.00 (1.03%)
M.Cap ( in Cr)54663.83
Bharat Parenterals (BSE)
peergroup  1701.80 (10.00%)
M.Cap ( in Cr)990.39
Alkem Laboratories (BSE)
peergroup  4857.90 (3.10%)
M.Cap ( in Cr)58083.48
NGL Fine-Chem (BSE)
peergroup  2711.85 (3.47%)
M.Cap ( in Cr)1675.39

Shareholding Pattern

FI/BANKS/INSURANCE 5.49%
PROMOTERS 33.47%
MUTUAL FUNDS/UTI 16.83%
NON-INSTITUTION 16.36%
GOVERNMENT 0%
FII 0%

About Cipla Ltd.

Cipla Ltd. was incorporated in the year 1935. Its today's share price is 1405.4. Its current market capitalisation stands at Rs 113471.29 Cr. In the latest quarter, company has reported Gross Sales of Rs. 165035.7 Cr and Total Income of Rs.162551.7 Cr. The company's management includes Rajendra Chopra, Mandar Purushottam Vaidya, Robert Stewart, PR Ramesh, Punita Lal, Ashok Sinha, Adil Zainulbhai, S Radhakrishnan, Umang Vohra, Samina Hamied, MK Hamied, Y K Hamied.

It is listed on the BSE with a BSE Code of 500087 , NSE with an NSE Symbol of CIPLA and ISIN of INE059A01026. It's Registered office is at Cipla House, Peninsula Business Park,Ganpatrao Kadam Marg,Lower ParelMumbai-400013, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are RGN Price & Co, RS Bharucha & Co, V Sankar Aiyar & Co, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.